Institution
University of New South Wales
Education•Sydney, New South Wales, Australia•
About: University of New South Wales is a education organization based out in Sydney, New South Wales, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 51197 authors who have published 153634 publications receiving 4880608 citations. The organization is also known as: UNSW & UNSW Australia.
Papers published on a yearly basis
Papers
More filters
••
McGill University1, New York University2, Mayo Clinic3, French Institute of Health and Medical Research4, Federal Institute for Drugs and Medical Devices5, University of New South Wales6, Rush University Medical Center7, University of California, Los Angeles8, Vancouver Hospital and Health Sciences Centre9, University of Pittsburgh10, Ludwig Maximilian University of Munich11, VU University Medical Center12, Women's College, Kolkata13, Case Western Reserve University14, Karolinska Institutet15
TL;DR: Mild cognitive impairment can be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension.
3,962 citations
••
University Health Network1, University of Southern California2, Merck & Co.3, National Autonomous University of Mexico4, University of Texas Health Science Center at Houston5, University of New South Wales6, Federal University of São Paulo7, Nottingham University Hospitals NHS Trust8, University of Maryland, Baltimore9, Northwestern University10
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Abstract: Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis. Methods We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis to receive either 50 mg of rofecoxib daily or 500 mg of naproxen twice daily. The primary end point was confirmed clinical upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers). Results Rofecoxib and naproxen had similar efficacy against rheumatoid arthritis. During a median follow-up of 9.0 months, 2.1 confirmed ga...
3,816 citations
••
University of Pennsylvania1, University of New South Wales2, Mayo Clinic3, University of California, Los Angeles4, University of California, San Francisco5, Erasmus University Rotterdam6, Johns Hopkins University7, University of Western Ontario8, University Hospital Southampton NHS Foundation Trust9, University of Southampton10, University College London11, University of California, San Diego12, University of Toronto13, Northwestern University14, Harvard University15, Technische Universität München16, Lille University of Science and Technology17, VU University Amsterdam18, Favaloro University19, Kessler Foundation20, Vita-Salute San Raffaele University21
TL;DR: The revised criteria for behavioural variant frontotemporal dementia improve diagnostic accuracy compared with previously established criteria in a sample with known frontotmporal lobar degeneration and reflect the optimized diagnostic features, less restrictive exclusion features and a flexible structure that accommodates different initial clinical presentations.
Abstract: Based on the recent literature and collective experience, an international consortium developed revised guidelines for the diagnosis of behavioural variant frontotemporal dementia. The validation process retrospectively reviewed clinical records and compared the sensitivity of proposed and earlier criteria in a multi-site sample of patients with pathologically verified frontotemporal lobar degeneration. According to the revised criteria, 'possible' behavioural variant frontotemporal dementia requires three of six clinically discriminating features (disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/compulsive behaviours, hyperorality and dysexecutive neuropsychological profile). 'Probable' behavioural variant frontotemporal dementia adds functional disability and characteristic neuroimaging, while behavioural variant frontotemporal dementia 'with definite frontotemporal lobar degeneration' requires histopathological confirmation or a pathogenic mutation. Sixteen brain banks contributed cases meeting histopathological criteria for frontotemporal lobar degeneration and a clinical diagnosis of behavioural variant frontotemporal dementia, Alzheimer's disease, dementia with Lewy bodies or vascular dementia at presentation. Cases with predominant primary progressive aphasia or extra-pyramidal syndromes were excluded. In these autopsy-confirmed cases, an experienced neurologist or psychiatrist ascertained clinical features necessary for making a diagnosis according to previous and proposed criteria at presentation. Of 137 cases where features were available for both proposed and previously established criteria, 118 (86%) met 'possible' criteria, and 104 (76%) met criteria for 'probable' behavioural variant frontotemporal dementia. In contrast, 72 cases (53%) met previously established criteria for the syndrome (P < 0.001 for comparison with 'possible' and 'probable' criteria). Patients who failed to meet revised criteria were significantly older and most had atypical presentations with marked memory impairment. In conclusion, the revised criteria for behavioural variant frontotemporal dementia improve diagnostic accuracy compared with previously established criteria in a sample with known frontotemporal lobar degeneration. Greater sensitivity of the proposed criteria may reflect the optimized diagnostic features, less restrictive exclusion features and a flexible structure that accommodates different initial clinical presentations. Future studies will be needed to establish the reliability and specificity of these revised diagnostic guidelines.
3,706 citations
••
University of California, San Francisco1, University of Trento2, Johns Hopkins University3, Northwestern University4, University of Western Ontario5, University of California, Los Angeles6, Vita-Salute San Raffaele University7, University College London8, University of Toronto9, Mayo Clinic10, University of California, Davis11, Katholieke Universiteit Leuven12, University of Cambridge13, University of New South Wales14, University of Pennsylvania15
TL;DR: This article provides a classification of primary progressive aphasia (PPA) and its 3 main variants to improve the uniformity of case reporting and the reliability of research results.
Abstract: This article provides a classification of primary progressive aphasia (PPA) and its 3 main variants to improve the uniformity of case reporting and the reliability of research results. Criteria for the 3 variants of PPA—nonfluent/agrammatic, semantic, and logopenic—were developed by an international group of PPA investigators who convened on 3 occasions to operationalize earlier published clinical descriptions for PPA subtypes. Patients are first diagnosed with PPA and are then divided into clinical variants based on specific speech and language features characteristic of each subtype. Classification can then be further specified as “imaging-supported” if the expected pattern of atrophy is found and “with definite pathology” if pathologic or genetic data are available. The working recommendations are presented in lists of features, and suggested assessment tasks are also provided. These recommendations have been widely agreed upon by a large group of experts and should be used to ensure consistency of PPA classification in future studies. Future collaborations will collect prospective data to identify relationships between each of these syndromes and specific biomarkers for a more detailed understanding of clinicopathologic correlations.
3,635 citations
••
TL;DR: A "fast EP" (FEP) is proposed which uses a Cauchy instead of Gaussian mutation as the primary search operator and is proposed and tested empirically, showing that IFEP performs better than or as well as the better of FEP and CEP for most benchmark problems tested.
Abstract: Evolutionary programming (EP) has been applied with success to many numerical and combinatorial optimization problems in recent years. EP has rather slow convergence rates, however, on some function optimization problems. In the paper, a "fast EP" (FEP) is proposed which uses a Cauchy instead of Gaussian mutation as the primary search operator. The relationship between FEP and classical EP (CEP) is similar to that between fast simulated annealing and the classical version. Both analytical and empirical studies have been carried out to evaluate the performance of FEP and CEP for different function optimization problems. The paper shows that FEP is very good at search in a large neighborhood while CEP is better at search in a small local neighborhood. For a suite of 23 benchmark problems, FEP performs much better than CEP for multimodal functions with many local minima while being comparable to CEP in performance for unimodal and multimodal functions with only a few local minima. The paper also shows the relationship between the search step size and the probability of finding a global optimum and thus explains why FEP performs better than CEP on some functions but not on others. In addition, the importance of the neighborhood size and its relationship to the probability of finding a near-optimum is investigated. Based on these analyses, an improved FEP (IFEP) is proposed and tested empirically. This technique mixes different search operators (mutations). The experimental results show that IFEP performs better than or as well as the better of FEP and CEP for most benchmark problems tested.
3,412 citations
Authors
Showing all 51897 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Kessler | 274 | 1332 | 328983 |
Nicholas G. Martin | 192 | 1770 | 161952 |
John C. Morris | 183 | 1441 | 168413 |
Richard S. Ellis | 169 | 882 | 136011 |
Ian J. Deary | 166 | 1795 | 114161 |
Nicholas J. Talley | 158 | 1571 | 90197 |
Wolfgang Wagner | 156 | 2342 | 123391 |
Bruce D. Walker | 155 | 779 | 86020 |
Xiang Zhang | 154 | 1733 | 117576 |
Ian Smail | 151 | 895 | 83777 |
Rui Zhang | 151 | 2625 | 107917 |
Marvin Johnson | 149 | 1827 | 119520 |
John R. Hodges | 149 | 812 | 82709 |
Amartya Sen | 149 | 689 | 141907 |
J. Fraser Stoddart | 147 | 1239 | 96083 |